Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™. (19th November 2018)

• Record Type: Journal Article
• Authors: Povedano, M; Martínez, Y; Tejado, A; Arroyo, P; Tebe, C; Lorenzo, JL; Montero, J
• Is Part Of: Pain management. Volume 9:Number 2(2019)
• Page Start: 123
• Page End: 129
• Publication Date: 2018-11-19
• Subjects: carpal tunnel syndrome -- electromyography -- nucleotides -- pain; Pain -- Treatment -- Periodicals; 616.047205
• DOI: 10.2217/pmt-2018-0050
• Languages: English
• ISSNs: 1758-1869

Abstract

Aim: Carpal tunnel syndrome (CTS) is a very common entrapment neuropathy characterized by pain and paresthesia in the territory of the median nerve. Although this syndrome has a considerable impact on the patient's quality of life, its medical treatment is far from optimal.Material & methods: We performed an observational study to evaluate Nucleo CMP Forte TM in patients with electromyography-confirmed, mild–moderate CTS. Pain was assessed using a visual analog scale, electromyogram and the SF-36.Results: Pain decreased significantly after 6 months. Quality of life improved significantly in the pain dimensions. No significant differences were observed in electromyographic findings. No adverse events were reported.Conclusions: Nucleotides could prove useful for the nonsurgical treatment of CTS. Further studies are necessary to confirm this.